Consumer genetic tests could be giving false reassurance to those at heightened risk of cancers, according to findings presented at an international conference last week. 上周一次国际会议上公布的研究结果显示,消费者基因测试可能会给那些癌症风险更高的人带来虚假的安慰。 The study, by clinical genetic testing company Invitae, revealed that tests for breast and bowel cancer risk by direct-to-consumer companies such as 23andMe give negative results to the vast majority of those carrying DNA mutations in the genes under investigation. 这项由临床基因检测公司Invitae开展的研究显示,23andMe等直接面向消费者的公司对乳腺癌和肠癌风险的检测显示,绝大多数携带受测基因DNA突变的人检测结果都是阴性的。 "These tests should not be taken at face value at all, whether they are positive or negative," said Edward Esplin from Invitae ahead of the annual meeting of the American Society of Human Genetics in Houston, Texas. 在美国人类遗传学学会于德克萨斯州休斯顿召开年度会议之前,来自Invitae的爱德华·埃斯普林说:“这些检测不应该只看表面价值,无论检测结果是阳性还是阴性。” |